Work

ASCEND Phase 3 Trial Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (P5.330)

Year: 2017

Type: article

Source: Neurology

DOI: 10.1212/wnl.88.16_supplement.p5.330

Authors: Hans-Peter Hartung, Douglas Arnold, Mark Freedman, Eva Havrdova, Douglas Jeffery, Raju Kapoor, Aaron Miller, Finn Sellebjerg, Haihong Li, Nisha Lucas, Diego Cadavid, Nolan Campbell, Pei-Ran Ho, Deborah Steiner

Institutions: Heinrich Heine University Düsseldorf, Montreal Neurological Institute and Hospital, NeuroRx Research (Canada), University of Ottawa, Ottawa Hospital Research Institute, Charles University, General University Hospital in Prague, Piedmont HealthCare, National Hospital for Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, University of Copenhagen, Rigshospitalet, Danish Multiple Sclerosis Center, Biogen (United States)

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2795840338

FWCI: 0.43

Cites:

Cited by: 5

Related to: 10